FY2024 EPS Estimates for MDxHealth Raised by William Blair

MDxHealth SA (NASDAQ:MDXH) – William Blair lifted their FY2024 EPS estimates for shares of MDxHealth in a research note issued on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($1.08) per share for the year, up from their prior estimate of ($1.11). The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.53) EPS.

Several other research firms also recently weighed in on MDXH. Piper Sandler decreased their price target on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Lake Street Capital began coverage on MDxHealth in a report on Thursday, October 31st. They issued a “buy” rating and a $7.00 target price on the stock.

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $1.64 on Thursday. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The stock has a market capitalization of $2.56 million, a PE ratio of -1.08 and a beta of 1.43. The firm’s 50 day moving average price is $2.17 and its 200-day moving average price is $2.56. MDxHealth has a twelve month low of $1.57 and a twelve month high of $4.64.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, August 21st. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05). The firm had revenue of $22.16 million for the quarter, compared to analysts’ expectations of $20.66 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%.

Institutional Trading of MDxHealth

Institutional investors and hedge funds have recently modified their holdings of the company. OneDigital Investment Advisors LLC increased its stake in MDxHealth by 15.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after buying an additional 7,656 shares in the last quarter. Maven Securities LTD purchased a new position in MDxHealth in the 3rd quarter worth approximately $208,000. Perkins Capital Management Inc. boosted its stake in MDxHealth by 70.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock worth $1,555,000 after purchasing an additional 309,500 shares during the period. Finally, MVM Partners LLC grew its holdings in MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after buying an additional 150,000 shares in the last quarter.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.